Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional) | RFA DA 26 019

Opportunity Information: Apply for RFA DA 26 019

The National Institutes of Health (NIH) is offering a discretionary grant opportunity titled "Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional)," under funding opportunity number RFA-DA-26-019 (CFDA/Assistance Listing 93.279). The focus is on supporting small businesses through the SBIR mechanism, using the R41/R42 phases, to develop or advance analytical instrumentation and methods that can keep up with fast-changing drug threats in the illicit supply. The application due date listed is February 19, 2025, and the opportunity was created on November 4, 2024. While the listing notes small businesses as the primary eligible applicants, it also indicates there are additional eligibility details and potentially other eligible applicant types described in the full Notice of Funding Opportunity (NOFO).

The central problem the opportunity is trying to solve is that the illicit drug supply is changing quickly, with substances such as xylazine and nitazenes already appearing and other novel compounds likely to emerge. Public health and public safety responses depend on being able to identify what is actually present in real-world samples, not just what is suspected. In many frontline settings, rapid test strips are commonly used because they are quick, sensitive, inexpensive, and generally accurate for the specific drugs they are designed to detect. The limitation is that strips only work when a strip exists for the compound in question, and new threats often show up before any widely available strip has been developed, validated, manufactured, and distributed.

Because of that gap, the opportunity emphasizes the need for "sensitive and sample agnostic methods." In practical terms, that points to analytical approaches and instrumentation that do not rely on a single known target in the way a dedicated immunoassay strip does. Instead, the goal is to support tools that can detect and characterize a broad range of compounds, including newly emerging drugs and adulterants, when analyzing real-world materials. This could include instrumentation and workflows intended for rapid or field-forward use, as well as laboratory-based systems that improve sensitivity, specificity, throughput, or the ability to identify unknowns. The overall intent is to strengthen detection capability when the drug landscape changes faster than targeted, strip-based tests can adapt.

The funding instrument is a grant, and the activity category is listed as Education and Health, reflecting the public health and biomedical relevance of drug detection. The "Clinical Trials Optional" designation indicates applicants may propose projects that include clinical trial elements if appropriate, but they are not required to do so. In many technology-development SBIR efforts, this typically means a project could focus purely on instrument and method development and validation using relevant samples, or it could also include human-subjects components if the proposed development and testing plan genuinely requires it and meets NIH requirements.

In short, this NIH opportunity is aimed at helping small businesses build the next generation of analytical instrumentation and alternative detection methods capable of keeping pace with emerging substances in the drug supply, especially when no dedicated test strips exist yet. The emphasis is on sensitivity, broad applicability across different sample types, and real-world relevance so that new and evolving threats can be identified and understood quickly enough to inform harm reduction, surveillance, and response efforts.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279.
• This funding opportunity was created on 2024-11-04.
• Applicants must submit their applications by 2025-02-19. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Small businesses.

Apply for RFA DA 26 019

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: